LEXICON PHARMACEUTICALS, INC. Income Statement
LXRX|12 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$1M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$172M
FY2025
Net Income
-$177M
FY2025
LEXICON PHARMACEUTICALS, INC. reported $1M in revenue and $177M in net loss for FY2025. Revenue has declined at a 14.4% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $139.0K | $298.0K | $24.0M | $79.3M | $130.0M | $22.9M | $2.2M | $1.1M | $1.8M | $4.9M | $10.7M |
| Cost of Revenue | $85.0K | $0 | $0 | $1.9M | $0 | $0 | - | - | - | - | - | - |
| SG&A Expense | $114.0M | $48.1M | $32.3M | $47.2M | $43.2M | $23.8M | $19.4M | $17.1M | $17.0M | $17.4M | $19.4M | $19.4M |
| R&D Expense | $58.9M | $52.8M | $55.0M | $153.6M | $164.0M | $95.2M | $89.3M | $89.7M | $82.6M | $91.8M | $78.5M | $81.2M |
| Operating Income | -$171.8M | -$100.8M | -$87.1M | -$47.8M | -$127.2M | $1.5M | -$100.4M | -$102.4M | -$108.4M | -$114.1M | -$95.7M | -$90.0M |
| Interest Expense | - | - | - | $14.5M | $6.6M | $6.7M | $2.3M | $2.0M | $2.1M | $2.5M | $2.7M | $3.0M |
| Income Tax | $0 | $0 | $0 | - | - | $0 | -$70.0K | $0 | $0 | $0 | -$26.0K | -$102.0K |
| Net Income | -$177.1M | -$101.9M | -$87.8M | -$58.6M | -$131.4M | -$4.7M | -$100.3M | -$104.1M | -$110.2M | -$116.2M | -$101.8M | -$82.8M |
| EPS (Basic) | -$0.80 | -$0.62 | -$0.60 | -$0.53 | - | - | - | -$0.27 | - | - | - | - |
| EPS (Diluted) | -$0.80 | -$0.62 | -$0.60 | $1.16 | -$1.27 | -$0.05 | -$1.31 | -$0.27 | -$0.23 | -$0.34 | -$0.34 | -$0.57 |
| Shares Outstanding | 363.0M | 165.7M | 145.7M | 105.7M | 103.9M | 103.6M | 76.3M | 73.3M | 489.7M | 340.8M | 302.8M | - |
| Operating Margin | -14264.9% | -72489.2% | -29224.8% | -199.2% | -160.5% | 1.1% | -439.2% | -4607.2% | -9955.5% | -6170.6% | -1950.2% | -840.7% |
| Profit Margin | -14710.9% | -73341.0% | -29449.0% | -244.1% | -165.9% | -3.6% | -438.8% | -4686.1% | -10120.4% | -6285.3% | -2073.7% | -773.6% |